Shenzhen Capital Group Co-Leads $62M Round In Chinese Biopharmaceutical Firm Zelgen
January 15, 2018 — 13:25 CST
This Data Is Locked!
This area is available only to Subscribers.
Shenzhen Capital Group Co., Ltd, Minsheng Life Insurance and Share Capital have led a RMB400 million (US$62 million) series B round in Suzhou Zelgen Biosciences... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
